In a repetitive in vitro killing assay, CLDN6- or CLDN18.2-TCAR and CAR-BBζ T cells were challenged three times at 5- to 7-day intervals with tumor spheroids derived from CLDN6+ or CLDN18+ PA-1 cells (Fig. 2B). Here, CLDN18 is linked to neoplasm.